TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
This study, called TEMPUS ARIES, is observing people with cancer to understand how their cancer changes over time. Researchers will collect blood samples to look at circulating tumor DNA (ctDNA), which are tiny pieces of cancer DNA found in the blood. This is not a study testing a new treatment; you will receive your usual cancer care. The study aims to track changes in ctDNA over five years. You can join if you are 18 to 99 years old, have a cancer diagnosis, and are willing to provide blood samples and give your informed consent. About 500 people are expected to participate.
- Study design
- This is an observational study, meaning it watches participants without giving them a specific intervention. It plans to enroll about 500 participants.
- What's involved
- You would have additional blood samples collected at specific times, in addition to your standard cancer care.
- Compensation
- Not stated in the trial record.
- Follow-up
- Changes in ctDNA will be measured for five years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
At a glance
Conditions
Where it's being run
32 sites across 19 statesStudy leadership
- Michelle Ting-Lin, MD · STUDY_DIRECTOR · Tempus AI, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Changes in ctDNA from baseline, on-treatment and post-treatment blood samples.5 years
Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation.